Growth Metrics

Day One Biopharmaceuticals (DAWN) Equity Ratio (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Equity Ratio for 4 consecutive years, with 0.87 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 0.7% to 0.87 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.87 through Dec 2025, up 0.7% year-over-year, with the annual reading at 0.87 for FY2025, 0.7% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.87 at Day One Biopharmaceuticals, down from 0.88 in the prior quarter.
  • The five-year high for Equity Ratio was 0.97 in Q1 2022, with the low at 0.77 in Q2 2024.
  • Average Equity Ratio over 4 years is 0.91, with a median of 0.92 recorded in 2023.
  • The sharpest move saw Equity Ratio dropped 18.96% in 2024, then increased 15.91% in 2025.
  • Over 4 years, Equity Ratio stood at 0.95 in 2022, then dropped by 3.12% to 0.92 in 2023, then fell by 6.39% to 0.86 in 2024, then grew by 0.7% to 0.87 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.87, 0.88, and 0.89 for Q4 2025, Q3 2025, and Q2 2025 respectively.